Evidence map›Paper›PMID 24010836›Full record

ReviewBiochemistry. Biokhimiia2013

Heparan sulfate-protein binding specificity.

M A Nugent, J Zaia, J L Spencer

Abstract readReview
In one paragraph

Review in Biochemistry. Biokhimiia, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Heparan-6-Cancers · 2023
    Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Heparan Sulfate Proteoglycans in Human Colorectal Cancer.Analytical cellular pathology (Amsterdam) · 2018
    Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Heparan sulfate and heparin interactions with proteins.Journal of the Royal Society, Interface · 2015
    Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

M A NugentDepartment of Biochemistry, Boston University School of Medicine, Boston, MA 02118, USA. mnugent@bu.edu
J Zaia
J L Spencer
Boston University · US

Funding

XI INTERNATIONAL SYMPOSIUM ON AMYLOIDOSISP41RR010888 · NCRR · BOSTON UNIVERSITY MEDICAL CAMPUS · PI ZAIA, JOSEPH · 1996 to 2011
$18.6M
Mass Spectrometry Resource for Biology and MedicineP41GM104603 · NIGMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI COSTELLO, CATHERINE E. · 2012 to 2017
$10.4M
Elastase Injury of Pulmonary Extracellular MatrixR01HL088572 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI NUGENT, MATTHEW A · 2008 to 2012
$2.0M
Post-biosynthetic Remodeling of Heparan SulfateR01HL098950 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI ZAIA, JOSEPH · 2010 to 2013
$1.6M
NCRR NIH HHS P41 RR010888NHLBI NIH HHS R01 HL088572NHLBI NIH HHS R01HL088572NHLBI NIH HHS R01 HL098950NIGMS NIH HHS P41 GM104603
6 · The paper itself

Abstract

Heparan sulfate (HS) represents a large class of linear polysaccharides that are required for the function of all mammalian physiological systems. HS is characterized by a repeating disaccharide backbone that is subject to a wide range of modifications, making this class of macromolecules arguably the most information dense in all of biology. The majority of HS functions are associated with the ability to bind and regulate a wide range of proteins. Indeed, recent years have seen an explosion in the discovery of new activities for HS where it is now recognized that this class of glycans functions as co-receptors for growth factors and cytokines, modulates cellular uptake of lipoproteins, regulates protease activity, is critical to amyloid plaque formation, is used by opportunistic pathogens to enter cells, and may even participate in epigenetic regulation. This review will discuss the current state of understanding regarding the specificity of HS-protein binding and will describe the concept that protein binding to HS depends on the overall organization of domains within HS rather than fine structure.

Indexed as

AnimalsAntithrombin IIIFibroblast Growth FactorsHeparan SulfateHumansLeukocyte ElastaseProtein BindingProteinsAntithrombin IIIFibroblast Growth FactorsHeparan SulfateLeukocyte ElastaseProteins

Identifiers

PMID24010836
PMCPMC4108213
OpenAlexW2169023580

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.